$69.5 M

ATNM Mkt cap, 22-Jun-2018
Actinium Pharmaceuticals Net income (Q1, 2018)-6.3 M
Actinium Pharmaceuticals EBIT (Q1, 2018)-6.4 M
Actinium Pharmaceuticals Cash, 31-Mar-201826.8 M

Actinium Pharmaceuticals Financials

Actinium Pharmaceuticals Income Statement

Annual

USDFY, 2014FY, 2016

R&D expense

12.3 m

General and administrative expense

10.2 m9.3 m

Operating expense total

22.4 m9.3 m

EBIT

(22.5 m)(26.8 m)

Interest expense

866 5 k

Net Income

(24.7 m)(24.3 m)

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

R&D expense

4.5 m

General and administrative expense

830.7 k1.7 m2.4 m3.3 m3.8 m3.6 m1.8 m2.2 m2.8 m1.4 m3.3 m2.8 m1.9 m

Operating expense total

1.6 m4.1 m4.4 m7 m7.9 m7.4 m4.6 m6 m6.9 m7.1 m7.8 m7.2 m6.4 m

EBIT

(1.6 m)(4.1 m)(4.4 m)(7 m)(7.9 m)(7.4 m)(4.6 m)(6 m)(6.9 m)(7.1 m)(7.8 m)(7.2 m)(6.4 m)

Interest expense

1.3 k5.7 k1.6 k588 2.7 k1.7 k666

Interest income

30.3 k

Net Income

(1.4 m)(16.7 m)3.5 m(6.1 m)(3.1 m)(7.5 m)(3.9 m)(4.4 m)(6.6 m)(6.6 m)(8.1 m)(7.1 m)(6.3 m)

Actinium Pharmaceuticals Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

5.5 m6.7 m25.6 m20.5 m

Accounts Receivable

2.1 b

Inventories

218.4 k699.9 k803.5 k1.8 m

Current Assets

5.8 m7.4 m26.5 m22.4 m

PP&E

13.9 k127.7 k106.1 k88.5 k

Total Assets

5.8 m7.6 m26.6 m22.5 m

Accounts Payable

379 k2.3 m1.5 m4.2 m

Short-term debt

157.8 k283.6 k265.7 k

Current Liabilities

7.3 m9.5 m4.6 m4.5 m

Long-term debt

157.8 k283.6 k265.7 k

Total Debt

315.7 k567.1 k531.4 k

Total Liabilities

4.5 m

Additional Paid-in Capital

64.9 m89.3 m134.2 m154.5 m

Retained Earnings

(91.2 m)(112.2 m)(136.6 m)

Total Equity

(1.6 m)(1.9 m)22 m18 m

Debt to Equity Ratio

-0.2 x-0.3 x0 x

Debt to Assets Ratio

0.1 x0.1 x0 x

Financial Leverage

-3.7 x-3.9 x1.2 x1.3 x

Quarterly

USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

26 m24.8 m22.2 m20.5 m15.5 m17.1 m11.5 m26.8 m

Current Assets

26.2 m24.9 m23.2 m21.4 m17.1 m18.1 m12.5 m27.6 m

PP&E

86.2 k95.3 k115.6 k110 k91.2 k75.9 k70 k

Total Assets

26.3 m25 m23.3 m21.6 m17.3 m18.2 m13 m28.1 m

Accounts Payable

1 m888.5 k1.9 m1.4 m2.6 m4.8 m3.6 m6.4 m

Short-term debt

92.3 k178.1 k89.6 k

Current Liabilities

3.1 m2.2 m3.3 m2.5 m3 m5.4 m4.1 m6.4 m

Long-term debt

92.3 k178.1 k89.6 k

Total Debt

184.5 k356.2 k179.1 k

Total Liabilities

3.1 m2.2 m3.3 m2.5 m3 m5.4 m4.1 m6.4 m

Additional Paid-in Capital

125 m128.5 m136.6 m142.3 m144 m157.4 m160.5 m191.1 m

Retained Earnings

(101.7 m)(105.7 m)(116.6 m)(123.3 m)(129.9 m)(144.6 m)(151.7 m)(169.5 m)

Total Equity

23.3 m22.9 m20.1 m19.1 m14.2 m12.9 m8.9 m21.7 m

Financial Leverage

1.1 x1.1 x1.2 x1.1 x1.2 x1.4 x1.5 x1.3 x

Actinium Pharmaceuticals Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(10.8 m)(24.7 m)(21 m)(24.3 m)

Depreciation and Amortization

1.6 k37.9 k53.5 k77.5 k

Inventories

106.6 k(193.9 k)162.1 k(1 m)

Accounts Payable

(793.9 k)2.7 m

Cash From Operating Activities

(6.3 m)(14.3 m)(18.5 m)(20.8 m)

Purchases of PP&E

(16.6 k)(151.7 k)(47.8 k)(60 k)

Cash From Investing Activities

(16.6 k)(186.4 k)(47.8 k)(109.8 k)

Cash From Financing Activities

6.2 m15.7 m37.5 m15.8 m

Interest Paid

561 866 7.9 k5 k

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Net Income

(4.9 m)(16.7 m)(13.2 m)(19.3 m)(3.1 m)(10.5 m)(14.5 m)(4.4 m)(11 m)(17.6 m)(8.1 m)(15.1 m)(6.3 m)

Depreciation and Amortization

1.4 k9.5 k23.8 k10.4 k26.6 k43.4 k18.1 k37.6 k57.7 k20.9 k35.3 k12 k

Accounts Payable

236.3 k666.5 k1.4 m(1 m)(1.3 m)(1.4 m)378.9 k(94.8 k)1.1 m573.9 k(590.3 k)620.5 k

Cash From Operating Activities

(4.9 m)(2.5 m)(5.1 m)(9.3 m)(5.8 m)(11.1 m)(14.6 m)(4.8 m)(11 m)(16.5 m)(5.4 m)(12.5 m)(5.5 m)

Purchases of PP&E

(8 k)(1.7 k)(128.4 k)(150.9 k)(959 )(26.9 k)(27.6 k)(41.5 k)(42.7 k)(8.3 k)(16.7 k)(7 k)

Cash From Investing Activities

(8 k)(1.7 k)(128.4 k)(150.9 k)(959 )(26.9 k)(77.4 k)(91.3 k)(92.6 k)26.4 k(372.8 k)(7 k)

Cash From Financing Activities

3.3 m2.8 m14.3 m15.7 m18.4 m30.3 m32.7 m1.4 m5.9 m6.5 m1.9 m3.8 m14.9 m

Interest Paid

561 5.7 k7.3 k7.9 k2.7 k4.3 k5 k

Actinium Pharmaceuticals Ratios

USDY, 2018

Financial Leverage

1.3 x
Report incorrect company information